Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Genmab A/S

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

GMAB●NASDAQ
HealthcareBiotechnology
$29.32
$0.64(2.25%)
U.S. Market is Open · 14:16

Genmab A/S (GMAB)

Meyka AI Score

Z

Key Financials

Market Cap17.8B
P/E Ratio21.82
EPS (TTM)$1.39
ROE0.15%
Fundamental Analysis

AI Price Forecasts

1 Month$29.61
3 Months$31.46
1 Year Target$33.76

GMAB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Genmab A/S (NASDAQ: GMAB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Genmab A/S's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GMAB on the NASDAQ shows an RSI of 58.12, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $33.76 for the NASDAQ listing.

Key metrics behind Genmab A/S's NASDAQ-traded stock include a P/E ratio of 21.82 and a market capitalization of 17.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GMAB on the NASDAQ.

Price Performance (NASDAQ: GMAB)

1-Day Change
1.19%
5-Day Change
3.20%
1-Month Change
3.61%
3-Month Change
7.32%
6-Month Change
-9.03%
Year-to-Date (YTD) Change
-5.78%
1-Year Change
32.03%
3-Year Change
-22.43%
5-Year Change
-37.43%
All-Time (Max) Change
669.76%

Contact Information

https://www.genmab.com
45 70 20 27 28
Carl Jacobsens Vej 30, Copenhagen, CD, 2500

Company Facts

26,380 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions